Jennison Associates
LRMR icon

Jennison Associates’s Larimar Therapeutics LRMR Stock Holding History

Jennison Associates’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,837
Closed -$38.7M – 708
2015
Q3 		$38.7M Sell
100,837
-2,419
-2% -$1.09M 0.04% 346
2015
Q2 		$42.9M Buy
103,256
+23,788
+30% +$9.95M 0.04% 366
2015
Q1 		$37.8M Buy
79,468
+55,130
+227% +$26.2M 0.03% 372
2014
Q4 		$9.01M Sell
24,338
-9,342
-28% -$2.41M 0.01% 489
2014
Q3 		$7.94M Buy
+33,680
New +$7.63M 0.01% 492

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Jennison Associates's LRMR Position: Q4 2015 in Review

Jennison Associates sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 100,837 shares — an estimated $38.7M sold.

Jennison Associates first reported a position in LRMR in Q3 2014 and held it in 5 quarters. The position peaked at $42.9M in Q2 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Jennison Associates reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Jennison Associates sold 100,837 Larimar Therapeutics shares in Q4 2015, an estimated $38.7M.
  • Jennison Associates first reported a position in Larimar Therapeutics in Q3 2014 and held it in 5 quarters.
  • Jennison Associates's Larimar Therapeutics position peaked at $42.9M in Q2 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Jennison Associates's 13F filing for Q4 2015, filed 10 Feb 2016.